Phenylalanine promotes alveolar macrophage pyroptosis via the activation of CaSR in ARDS

Acute respiratory distress syndrome (ARDS) is associated with high mortality rates in patients admitted to the intensive care unit (ICU) patients with overwhelming inflammation considered to be an internal cause. The authors' previous study indicated a potential correlation between phenylalanin...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1114129
Main Authors Tang, Yiding, Yu, Yue, Li, Ranran, Tao, Zheying, Zhang, Li, Wang, Xiaoli, Qi, Xiaoling, Li, Yinjiaozhi, Meng, Tianjiao, Qu, Hongping, Zhou, Mi, Xu, Jing, Liu, Jialin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 12.06.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Acute respiratory distress syndrome (ARDS) is associated with high mortality rates in patients admitted to the intensive care unit (ICU) patients with overwhelming inflammation considered to be an internal cause. The authors' previous study indicated a potential correlation between phenylalanine levels and lung injury. Phenylalanine induces inflammation by enhancing the innate immune response and the release of pro-inflammatory cytokines. Alveolar macrophages (AMs) can respond to stimuli synthesis and release of inflammatory mediators through pyroptosis, one form of programmed cell death acting through the nucleotide-binging oligomerization domain-like receptors protein 3 (NLRP3) signaling pathway, resulting in the cleavage of caspase-1 and gasdermin D (GSDMD) and the release of interleukin (IL) -1β and IL-18, aggravating lung inflammation and injury in ARDS. In this study, phenylalanine promoted pyroptosis of AMs, which exacerbated lung inflammation and ARDS lethality in mice. Furthermore, phenylalanine initiated the NLRP3 pathway by activating the calcium-sensing receptor (CaSR). These findings uncovered a critical mechanism of action of phenylalanine in the context of ARDS and may be a new treatment target for ARDS.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Melanie Albrecht, Paul-Ehrlich-Institut (PEI), Germany
These authors have contributed equally to this work and share first authorship
Reviewed by: Pankaj Baral, Kansas State University, United States; Krzysztof Guzik, Jagiellonian University, Poland
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1114129